Flucloxacillin

Generic Name: Flucloxacillin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₁₇ClFN_₃O_₅S

CAS Number: 5250-39-5

Unique Ingredient Identifier: 43B2M34G2V

Background: Antibiotic analog of cloxacillin.

Indication: Used to treat bacterial infection by susceptible microorganisms.

Associated Conditions: Susceptible infections

Associated Therapies: -

Clinical Trials

Flucloxacillin as an Inducer of CYP-enzymes

Phase 1

Completed

Conditions: Healthy Volunteers
Drug Drug Interaction

Interventions: Drug: Flucloxacillin

First Posted Date: 2021-04-12

Last Posted Date: 2022-01-11

Lead Sponsor: University of Southern Denmark

Target Recruit Count: 14

Registration Number: NCT04840641

Locations: 🇩🇰
University of Southern Denmark, Odense, Region Of Southern Denmark, Denmark

Penicillin Against Flucloxacillin Treatment Evaluation

Phase 4

Withdrawn

Conditions: Staphylococcus Aureus

Interventions: Drug: Benzylpenicillin
Drug: Flucloxacillin

First Posted Date: 2018-08-15

Last Posted Date: 2022-11-16

Lead Sponsor: The University of Queensland

Registration Number: NCT03632642

Locations: 🇦🇺
Brisbane Private Hospital, Brisbane, Queensland, Australia

Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion to ICU Patients

Completed

Conditions: Bacterial Infections

First Posted Date: 2016-12-15

Last Posted Date: 2018-10-23

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 30

Registration Number: NCT02993575

Locations: 🇳🇱
Radboud University Medical Center, Nijmegen, Netherlands

Penicillin for the Emergency Department Outpatient Treatment of CELLulitis

Phase 4

Conditions: Cellulitis
Wound Infection
Abscess

Interventions: Drug: Flucloxacillin
Drug: Placebo (for phenoxymethylpenicillin)
Drug: Phenoxymethylpenicillin

First Posted Date: 2016-10-04

Last Posted Date: 2016-10-04

Lead Sponsor: Royal College of Surgeons, Ireland

Target Recruit Count: 414

Registration Number: NCT02922686

Locations: 🇮🇪
Department of Emergency Medicine, Connolly Hospital,, Blanchardstown, Dublin, Ireland
🇮🇪
Department of Emergency Medicine, Mercy University Cork, Cork, Greenville Place, Ireland
🇮🇪
Beaumont Hospital,, Dublin, Ireland

and more 2 locations

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Phase 3

Completed

Conditions: Bacterial Infections
Methicillin-Resistant Staphylococcus Aureus
Staphylococcal Skin Infections

Interventions: Drug: Dalbavancin
Drug: Vancomycin
Drug: Oxacillin
Drug: Flucloxacillin
Drug: Cefadroxil
Drug: Clindamycin

First Posted Date: 2016-06-28

Last Posted Date: 2024-01-17

Lead Sponsor: AbbVie

Target Recruit Count: 199

Registration Number: NCT02814916

Locations: 🇱🇹
Klaipeda Children's Hospital /ID# 235652, Klaipeda, Lithuania
🇧🇬
University Multiprofile Hospital for Active Treatment Deva Maria EOOD Burgas /ID# 235965, Bulgas, Bulgaria
🇧🇬
MHAT (Multiprofile Hospital for Active Treatment) /ID# 235539, Kozloduy, Bulgaria

and more 81 locations

Comparing the Intravenous Treatment of Skin Infections in Children, Home Versus Hospital

Not Applicable

Completed

Conditions: Cellulitis

Interventions: Other: Home
Other: Ward
Drug: flucloxacillin
Drug: ceftriaxone

First Posted Date: 2015-01-08

Last Posted Date: 2022-11-08

Lead Sponsor: Murdoch Childrens Research Institute

Target Recruit Count: 190

Registration Number: NCT02334124

Locations: 🇦🇺
The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia

Duration of ANtibiotic Therapy for CEllulitis

Phase 4

Terminated

Conditions: Erysipelas
Cellulitis

Interventions: Drug: Flucloxacillin
Drug: Placebo (for flucloxacillin)

First Posted Date: 2014-01-10

Last Posted Date: 2017-10-10

Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Target Recruit Count: 151

Registration Number: NCT02032654

Locations: 🇳🇱
Diakonessenhuis, Utrecht, Netherlands
🇳🇱
Flevoziekenhuis, Almere, Flevoland, Netherlands
🇳🇱
Sint Lucas Andreas Ziekenhuis, Amsterdam, Noord-Holland, Netherlands

and more 8 locations

Adjunctive Clindamycin for Cellulitis: C4C Trial.

Phase 4

Completed

Conditions: Cellulitis

Interventions: Drug: Flucloxacillin
Drug: Placebo oral capsule
Drug: Clindamycin

First Posted Date: 2013-06-12

Last Posted Date: 2022-08-17

Lead Sponsor: University Hospitals Bristol and Weston NHS Foundation Trust

Target Recruit Count: 410

Registration Number: NCT01876628

Locations: 🇬🇧
University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom

Staphylococcus Aureus Bacteremia Antibiotic Treatment Options

Phase 3

Completed

Conditions: Staphylococcus Aureus Infection

Interventions: Drug: Trimethoprim-Sulfamethoxazole
Drug: Flucloxacillin
Drug: Clindamycin
Drug: Cloxacillin
Drug: Linezolid
Drug: Vancomycin
Drug: Daptomycin
Drug: Cefazolin

First Posted Date: 2013-02-15

Last Posted Date: 2020-05-27

Lead Sponsor: Heinrich-Heine University, Duesseldorf

Target Recruit Count: 215

Registration Number: NCT01792804

Locations: 🇳🇱
Amsterdam, Amsterdam, Netherlands
🇳🇱
Tilburg, Tilburg, Netherlands
🇳🇱
Diakonessenhuis Utrecht, Utrecht, Netherlands

and more 37 locations

The Effect of Antimicrobial Therapy on the Serum Level of P-cresol in Peritoneal Dialysis Patients

Phase 1

Terminated

Conditions: Chronic Kidney Disease

Interventions: Drug: Flucloxacillin

First Posted Date: 2007-02-09

Last Posted Date: 2020-04-27

Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Target Recruit Count: 9

Registration Number: NCT00433342

Locations: 🇧🇪
Universitaire Ziekenhuizen Leuven, Leuven, Vlaams-Brabant, Belgium

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy